Table of contents

Key facts

Active substance
Anti-C1s Humanized IgG4 Monoclonal Antibody
Therapeutic area
  • Haematology-Hemostaseology
  • Immunology-Rheumatology-Transplantation
  • Neurology
Decision number
PIP number
Pharmaceutical form(s)
  • Solution for injection
  • Solution for infusion
Condition(s) / indication(s)
Treatment of chronic inflammatory demyelinating polyradiculo-neuropathy
Route(s) of administration
  • Intravenous use
  • Subcutaneous use
Contact for public enquiries
Genzyme Europe B.V.

E-mail: eumedinfo.gz@sanofi.com
Tel: +31 202453917

Decision type
W: decision granting a waiver in all age groups for all conditions or indications


How useful was this page?

Add your rating